Experts in Africa cautious on potential malaria vaccine (Update)

October 8, 2013

Experts in Africa, the continent worst-hit by malaria, reacted with optimism but also caution on Tuesday to news that the first vaccine against the killer disease may soon reach the market.

GlaxoSmithKline said it was seeking approval for a prototype vaccine that reduced the risk of malaria by almost half among children aged between five and 17 months, and by around a quarter among infants aged between six and 12 weeks.

"This is the first vaccine against malaria," Sophie Biernaux, a malaria vaccine leader at GSK, told AFP in Durban.

If the British drugmaker's application is successful, the vaccine could be rolled out within two years.

The mosquito-borne disease kills an estimated 660,000 people each year, 90 percent of them in Africa, with the majority being children under five.

"This is great hope for Africa," Nilton Saraivo, a manager of Angola's national anti-malaria programme, told AFP.

But others were more cautious.

In Gabon, one of the countries where clinical trials were conducted, researcher Bertrand Lell said the vaccine's efficacy "is not very large" compared to vaccines such as the one against polio.

"But given the prevalence of malaria in Africa, you can imagine the impact it will have on people if the mortality rate is down 50 percent," said Lell, of the Lambarene Centre for Medical Research.

In the Democratic Republic of Congo—which has the world's second-highest malaria death rate after Nigeria—SANRU, an organisation that distributes mosquito nets to fight malaria, said it was too early to declare victory.

It noted that the vaccine did not offer a complete shield, although trials—including assessment of a booster shot—are ongoing.

"This is good news as long as the vaccine shows a required level of efficacy," said John Gikapa, technical advisor to SANRU.

The research was carried out at 11 centres in seven African countries, covering more than 15,000 infants and children.

GSK said it would now file an application to the European Medicines Agency (EMA) under a process aimed at marketing new drugs for poorer countries.

The European medications watchdog will then give a "scientific opinion" on the vaccine's safety and efficacy.

This opens the way for it to be considered by the World Health Organisation (WHO), which in turn can fast-track its licensing in individual countries in Africa.

The vaccine—called RTS,S—is a frontrunner in the race to develop the first immunisation for malaria.

The results for the Phase III trial were unveiled Tuesday at a conference in South Africa.

They are sure to raise as many questions as answers.

As well as offering less protection for very small children, the vaccine's effectiveness declined over time, data showed.

"There are a number of possible hypotheses for these differences" in effectiveness, said Lucas Otieno of the Kenya Medical Research Institute, one of the principal investigators in the trial.

The theories include possible interference with the vaccine by maternal antibodies and the impact of other vaccines administered around the same time, he said.

'Any progress welcome'

Experts are also wary about the logistics of administering the vaccine in Africa, where the people most at risk often live in poverty-stricken and difficult-to-access places.

Just getting drugs to where they are needed can be a headache, requiring proper handling in hot, humid environments and secure storage in countries where theft or corruption may be rampant.

"Any progress on fighting malaria is very welcome, and this vaccine could be another important weapon in our armoury," said Martin de Smet, a malaria specialist with Doctors Without Borders (MSF).

"Delivering injection-based vaccines in the kind of environments where malaria is prominent is also hugely challenging—even for treatments that are 100-percent effective," he said.

"Locations are traditionally remote, with people having to walk for days to get to a health facility, and often require refrigeration."

GSK said if it gets the green light, the vaccine would probably be distributed through agencies such as the United Nations Children's Fund and the GAVI Alliance, a public-private health partnership.

The price would cover the cost of manufacturing plus a margin of five percent which would be ploughed into research for next-generation vaccines, a GSK spokesman said.

Explore further: GSK to seek green light for malaria vaccine

Related Stories

GSK to seek green light for malaria vaccine

October 8, 2013
British drug maker GlaxoSmithKline (GSK) said on Tuesday it hoped to get the green light for a prototype vaccine against malaria after trials showed it offered children a partial shield against the disease.

Malaria vaccine candidate reduces disease over 18 months of follow-up in phase 3 children's study

October 7, 2013
Results from a large-scale Phase III trial, presented today in Durban, show that the most clinically advanced malaria vaccine candidate, RTS,S, continued to protect young children and infants from clinical malaria up to 18 ...

Malaria vaccine fails to work after four years

March 20, 2013
A new vaccine that has raised hopes of becoming a potent new tool in the battle against malaria seems to stop working in children after four years, according to research published Wednesday.

Malaria vaccine a letdown for infants (Update)

November 9, 2012
An experimental malaria vaccine once thought promising is turning out to be a disappointment, with a new study showing it is only about 30 percent effective at protecting infants from the killer disease.

Malaria vaccine candidate, RTS,S reduces the risk of malaria by half in African children

October 18, 2011
First results from a large-scale Phase III trial of RTS,S*, published online today in the New England Journal of Medicine (NEJM), show the malaria vaccine candidate to provide young African children with significant protection ...

Australian researchers close in on malaria vaccine

July 2, 2013
Australian researchers said Tuesday they were closing in on a potential vaccine against malaria, with a study showing their treatment had protected mice against several strains of the disease.

Recommended for you

Pair of discoveries illuminate new paths to flu and anthrax treatments

October 17, 2017
Two recent studies led by biologists at the University of California San Diego have set the research groundwork for new avenues to treat influenza and anthrax poisoning.

Portable 3-D scanner assesses patients with elephantiasis

October 17, 2017
An estimated 120 million people worldwide are infected with lymphatic filariasis, a parasitic, mosquito-borne disease that can cause major swelling and deformity of the legs, a condition known as elephantiasis. Health-care ...

New tools to combat kidney fibrosis

October 16, 2017
Interstitial fibrosis – excessive tissue scarring – contributes to chronic kidney disease, which is increasing in prevalence in the United States.

How hepatitis C hides in the body

October 13, 2017
The Hepatitis C (HCV) virus is a sly enemy to have in one's body. Not only does it manage to make itself invisible to the immune system by breaking down communication between the immune cells, it also builds secret virus ...

Largest study yet of malaria in Africa shows historical rates of infection

October 12, 2017
(Medical Xpress)—A team of researchers with members from the Kenya Medical Research Institute, the University of Oxford and the University of KwaZulu-Natal has conducted the largest-ever study of the history of malaria ...

Promising new target for treatment of psoriasis is safe, study shows

October 11, 2017
A protein known to play a significant role in the development of psoriasis can be prevented from functioning without posing a risk to patients, scientists at King's College London have found.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.